NDTV Profit’s special research section collates quality and in-depth equity and economy research reports from across India’s top brokerages, asset managers and research agencies. These reports offer NDTV Profit’s subscribers an opportunity to expand their understanding of companies, sectors and the economy.
Nirmal Bang Report
Rossari Biotech Ltd.’s Q4 FY24 performance came broadly in-line with our estimates on the back of continued growth in various sections of HPPC segment.
Sequential decline in gross margin (192 basis points) was on account of inferior mix along with moderation in selling prices. The management indicated improvement going forward and expect gross margin to settle at ~30%.
Existing capacity ramp up, commissioning of new capacities along with growth drivers in various sections of HPPC makes a plausible case for double digit volume growth in next two years.
Maintain Buy (25 times price-to-earning FY26E).
Click on the attachment to read the full report:
DISCLAIMER
This report is authored by an external party. NDTV Profit does not vouch for the accuracy of its contents nor is responsible for them in any way. The contents of this section do not constitute investment advice. For that you must always consult an expert based on your individual needs. The views expressed in the report are that of the author entity and do not represent the views of NDTV Profit.
Users have no license to copy, modify, or distribute the content without permission of the Original Owner.
RECOMMENDED FOR YOU
Varun Beverages Q2 Results Review — Yes Securities Maintains 'Buy', Revises Target Price
Jul 30, 2025
'Buy' L&T Shares Maintains Motilal Oswal On Above Estimate Q1 Results, Hikes Target Price
Jul 30, 2025
Suryoday SFB— Well-Positioned For A Valuation Multiple Re-Rating, Says Centrum Post Q1 Result; Maintains 'Buy'
Jul 28, 2025
Rossari Biotech Q1 Results — HPPC, New Capacities To Drive Earnings Growth, Says DRChoksey Maintaining Buy
Jul 25, 2025
POPULAR